Monday, July 26, 2010

Publish data on drug trials — even when it’s not flattering - The Boston Globe

Until now, the industry’s track record has left much to be desired. Currently, companies seeking approval for new drugs must supply basic information about all their completed studies with ClinicalTrials.gov, a government website. But fewer than half of the studies registered there are published in journals. One-quarter to one-half of clinical trials for drugs that gained Food and Drug Administration approval remain unpublished several years later. A much higher proportion of the unpublished studies turn out to have unfavorable results for the marketed treatment.

Posted via email from Jack's posterous

No comments: